arrow
B

Boris Mankovsky

KU Leuven
H指数:22
被引数:5,334

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism

EndoCompass 项目:糖尿病、肥胖和代谢研究路线图

2025-12-010
PRE
EndoCompass project: research roadmap for diabetes, obesity, and metabolism

EndoCompass项目:糖尿病、肥胖和代谢研究的路线图

2025-10-010
PRE
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

CVOT峰会报告2024:新的心血管、肾脏和代谢结局

2025-05-020
OA
Expert Clinical Interpretation of Continuous Glucose Monitor Reports From Individuals Without Diabetes
2025-02-120
OA
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
2024-03-194
OAAI
Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society

糖尿病患者心力衰竭诊断的生物标志物: 糖尿病技术协会的共识报告

2023-07-019
OAAI
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
2023-03-168
OAAI
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

Finerenone及其对慢性肾脏病和2型糖尿病患者死亡率的影响: 保真度分析

2023-01-1321
OAAI
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
2022-11-24318
OA
Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations

临床实践中糖尿病感觉运动性多发性神经病的筛查,诊断和管理: 国际专家共识建议

2022-04-0187
OAAI
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

通过临床医生评级验证的连续血糖监测的低血糖和高血糖的血糖风险指数 (GRI)

2022-03-29114
OA
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
2020-10-23105
OAAI
Prevalence and correlates of depressive disorders in people with Type 2 diabetes: results from the International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study, a collaborative study carried out in 14 countries
2018-03-30101
PREAI